Major Depressive Disorder (MDD) is a chronic, disabling, prevalent and life-threatening, biologically based disorder.(1,2) The prevalence of MDD continues to rise and the reporting of psychological symptoms has been particularly influenced by the COVID-19 pandemic.(3) Despite a broad array of available oral antidepressant options, all of which are predominantly monoaminergic-based, current treatment options continue to have limitations.(1) These limitations include prolonged time to clinically meaningful response, low rates of response and remission, and associated tolerability issues that can negatively impact patients’ lives and affect medication adherence.(1) This session will review the extent and impact of MDD, the current challenges with existing treatments, and new exploratory pathways in treating MDD and the potential to improve clinical outcomes.
1. Gerhard DM, Wohleb ES, Duman RS. Drug Discov Today. 2016;21(3):454-64.
2. Huang YJ, Lane HY, Lin CH. Neural Plast. 2017;2017:4605971.
3. Ettman CK, Abdalla SM, Cohen GH. JAMA Netw Open. 2020;3(9):e2019686.
Learn about the pivotal clinical data and a pilot study that evaluated the next-dose transition from a treatment to this treatment option.